NewTimeSpace (newtimespace.com) News, on August 31, 2026, the chip theme traded in a choppy session, with ASMPT (00522.HK) edging up. As of 13:47, the stock was quoted at HKD 161.100, up 0.12%.
NewTimeSpace (newtimespace.com) News, on August 31, 2026, the robotics theme fluctuated higher, while XIAOMI-W (01810.HK) weakened. As of 13:32, the stock was quoted at HKD 27.660, down 0.58%.
NewTimeSpace News: On 31 August 2026, ABBISKO-B (02256.HK) announced that the first patient has been dosed in the Phase I trial of ABSK211, an oral small-molecule pan-KRAS inhibitor developed by its subsidiary Abbisko, in patients with advanced solid tumors harboring KRAS alterations; preclinically, ABSK211 demonstrated broad-spectrum potent inhibition across G12D/G12C/G12S/G12V/G13D and wild-type amplification subtypes, with combination potential with PRMT5 inhibitors, cetuximab, immunotherapy and chemotherapy; it has received IND approvals from China's NMPA and the US FDA, with global clinical development advancing.
NewTimeSpace News: On 31 August 2026, SBP GROUP (01177.HK) announced that the final Phase I data of Kylo-11 (LPA siRNA), a Class 1 innovative drug developed by its wholly-owned subsidiary Hejiya Biomedical, were presented at ESC 2026 as an LBCT oral presentation and published in full in The Lancet; among 70 subjects, a single dose significantly and durably reduced Lp(a), with mid-to-high dose groups achieving reductions of 94.6%-97.0% at week 48, approaching maximum reduction within about 4 weeks in the 225 mg and above groups and maintained through week 48, supporting the "once-a-year" dosing strategy; no serious adverse events occurred and tolerability was generally good; a Phase II study is underway in China and the US.
NewTimeSpace News: On 31 August 2026, HUTCHMED (00013.HK) announced that the SANOVO Phase III study in China of ORPATHYS plus TAGRISSO in treatment-naive EGFR-mutant NSCLC with MET overexpression met its primary endpoint, demonstrating a statistically significant and highly clinically meaningful PFS improvement in both the high-MET and ITT populations, with encouraging OS benefit; the study enrolled 326 patients (NCT05009836), with a safety profile consistent with known profiles; the combination is already approved in China for previously treated patients based on SACHI, and the SAFFRON global Phase III also reported positive data in August 2026.
NewTimeSpace News: On 30 August 2026, ASCLETIS-B (01672.HK) announced that the first subject has been dosed in the global Phase III program (AURORA-1/AURORA-2, ~4,600 subjects) of once-daily oral small-molecule GLP-1 receptor agonist ASC30 for long-term weight management; topline data are expected in Q3 2028, with an NDA to the US FDA by end-2028 and an MAA to the EMA in early 2029, and if approved ASC30 could become the second oral small-molecule GLP-1 agonist launched in the US and Europe; the pipeline also includes GLP-1/GIP dual-target and triple-target fixed-dose combinations.
NewTimeSpace News: On 28 August 2026, TONG REN TANG (01666.HK) announced that its subsidiary obtained a Certificate of Registration of Chinese Patent Medicine (No. HKC-18820, valid until 25 August 2031) from the Chinese Medicine Council of Hong Kong, permitting the sale of Sanzi Yangqin Granules (Tong Ren Tang) in Hong Kong; cumulative R&D investment in the product was approximately HKD 800,000 (unaudited) and the product has not yet been marketed, while the certificate is not expected to have a material impact on the Group's operations and results for the time being.
On August 28, 2026, Hong Kong's three major indices closed mixed, with AI concept stocks diverging on the day and most large-model and AI chip sectors weakening. The Hang Seng Index rose 0.07%, the Hang Seng TECH Index fell 0.33%, and the Hang Seng China Enterprises Index closed flat.In the embodied-AI segment, UBTECH ROBOTICS (09880.HK) closed up 0.66%, XIAOMI-W (01810.HK) rose 1.24%.
NewTimeSpace News: On 28 August 2026, CSPC PHARMA (01093.HK) announced that the Phase II clinical trial (SYH2069-004) of SYH2069 Injection for weight management in overweight or obese adult patients had been officially launched at the first study site in China; the product is a GLP-1R/GIPR dual-target dual-biased agonist that obtained the NMPA Drug Clinical Trial Approval Notice in December 2025.
NewTimeSpace News: On 28 August 2026, SBP GROUP (01177.HK) announced that LM-364 "Nectin-4ᵀᴹᴱ ADC", a national Class 1 innovative drug independently developed by wholly-owned subsidiary LaNova Medicines, had obtained implied clinical trial approval from China's NMPA for advanced solid tumors, after receiving FDA approval and initiating clinical trials in Australia in April this year; preclinical data disclosed at the 2026 AACR Annual Meeting showed TGI of up to 168.79% across PDX models.
NewTimeSpace News: On 28 August 2026, SHANDONG XINHUA (00719.HK) announced that its Dapoxetine Hydrochloride Tablets had obtained the Drug Registration Certificate from the National Medical Products Administration, with approval number Guoyao Zhunzi H20265706, at a specification of 30 mg under Chemical Drug Category 4, following an application filed and accepted in April 2025; dapoxetine sales in Chinese public medical institutions reached approximately RMB 1.03 billion in 2025, and the Company said the product would further enrich its formulation portfolio.
NewTimeSpace News: On August 28, 2026, RoboSense (02498.HK) trended weaker in afternoon trading. As of 15:17, the stock was quoted at HK$18.87, down 2.02%.
NewTimeSpace (newtimespace.com) News, on August 26, 2026, the chip theme weakened, with SMIC (688981.SH) fluctuating lower. As of 13:23, the company was quoted at HK$70.850, down 0.63%.
NewTimeSpace (newtimespace.com) News, on August 28, 2026, the robotics theme weakened amid volatility, while UBTECH ROBOTICS (09880.HK) rose marginally against the trend. As of 13:11, the company was quoted at HK$83.150, up 0.24%.
NewTimeSpace News: On 28 August 2026, HUTCHMED (00013.HK) announced conditional NMPA approval of fanregratinib (ATLED) for advanced cholangiocarcinoma with FGFR2 fusions or rearrangements, supported by a pivotal Phase II registration cohort with an IRC-assessed objective response rate of 42.5%.
NewTimeSpace News: On 27 August 2026, TYK MEDICINES-B (02410.HK) announced that its self-developed next-generation EGFR-TKI dovatinib mesylate tablets (TY-9591) have been granted conditional NMPA approval for the first-line treatment of adult patients with locally advanced or metastatic NSCLC harboring EGFR 19del or L858R mutations with CNS metastases; the drug is a differentiated deuterated innovation derived from osimertinib, and the Company has initiated multiple monotherapy and combination studies around the product.
